285 results about "Central nervous system disease" patented technology

The invention relates to the technical field of antibodies, in particular to a pH-sensitive humanized anti-transferrin receptor 1 antibody. The invention designs a pH-sensitive human anti-transferrin receptor 1 antibody or an antigen binding fragment thereof, the antibody has good binding activity to TfR1 under a neutral pH condition, the binding activity is obviously reduced or lost under a low pH condition, and the antibody can more efficiently penetrate through a blood-brain barrier to be delivered into the brain through a TfR1-mediated endocytosis transport effect by utilizing the pH-sensitive characteristic, so that the human anti-transferrin receptor 1 antibody or the antigen binding fragment thereof can be applied to the brain. The drug delivery system can be used as a delivery carrier of drugs for treating central nervous system diseases, and has a wide application prospect.

The invention relates to double-encapsulated lipid nanoparticles entering brain through nose and a preparation method and application thereof, the double-encapsulated lipid nanoparticles comprise lipid nanoparticles, drugs in the lipid nanoparticles and rana odorata lectin coupled to the surfaces of the lipid nanoparticles, and the drugs comprise hydrophilic drugs and hydrophobic drugs. According to the invention, the rana odorata lectin and the lipid nanoparticles are coupled, and the rana odorata lectin can be specifically combined with L-fucose residues expressed by olfactory epithelial cells, so that the adhesion of the lipid nanoparticles to olfactory epithelium during nasal administration is enhanced, and the brain entering efficiency of the lipid nanoparticles is finally improved. After entering the brain, the lipid nanoparticles respond to diseased regions with high active oxygen content so as to release drugs. In addition, double-drug encapsulation can target different pathogenesis of central nervous system diseases, and the limitation that a traditional treatment drug is single in action target is improved.

The invention discloses a pharmaceutical composition which comprises anisodine or salt thereof and 2-borneol or related substances thereof. The pharmaceutical composition provided by the invention has a synergistic effect in treatment of cardia-cerebrovascular diseases, especially central nervous diseases such as acute ischemic stroke, can effectively improve the effect of patients with cerebrovascular diseases, especially central diseases such as acute ischemic stroke, and improves the quality of life.

The invention discloses a novel injection containing edaravone and high-purity synthesized (+)-2-borneol, because the (+)-2-borneol is prepared by a chemical synthesis process, the curative effect of the (+)-2-borneol is better than that of natural borneol and (+)-2-borneol extracted from the natural borneol under the same dosage, the toxic and side effects can be reduced, and the product quality is more stable; and the established GC-MS analysis method can more accurately control the content of each coexisting substance and better guarantee the shelf life quality. The injection is more suitable for improving the treatment effect on central nervous system diseases, oxidative stress injuries such as diabetes, retinopathy, diabetic peripheral neuropathy and neurodegenerative diseases and thrombus-related diseases.

There are disclosed phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the disclosed compounds.

Provided are a Parabacteroides strain, a culture, a microbial agent and the use thereof. Specifically provided is a Parabacteroides strain, which can be a strain having a deposit number of GDMCC No: 62664 or 62665, or a strain having at least 96.74% identity to the 16S rRNA of the strain, and / or a strain having at least 87% average nucleotide identity to the genome of the strain. The strain or a product based on the strain has good effects in terms of preventing or treating tumors or cancers, metabolic diseases, inflammation or autoimmune diseases, infectious diseases and central nervous system diseases.

The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.

The present disclosure provides oligonucleotides comprising at least one radical of a central nervous system receptor ligand at a nucleobase, the 2' position of a nucleoside, or the 3' position of a nucleoside. The present disclosure also provides pharmaceutical compositions and kits comprising said oligonucleotides, methods of delivering said oligonucleotides, methods of modulating the activity of a protein using such oligonucleotides, and methods of treating, preventing, or diagnosing diseases (e.g., central nervous system diseases, neurodegenerative diseases, and neurocognitive diseases) in a. subject in need thereof using said oligonucleotides or pharmaceutical compositions thereof. The present disclosure also provides oligonucleosides that may be useful for making the oligonucleotides.

The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.

The invention relates to particular prodrugs and analogs of (3α,5α)-3-hydroxy-21-(1H-imidazol-1-yl)-3-methoxymethyl)-pregnan-20-one, in free or pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as sedatives, hypnotics, anxiolytics, and / or anesthetics, and methods for treatment of depression, anxiety, insomnia, epilepsy, and other central nervous system disorders, as well as to combinations with other agents.

The present invention relates to a novel compound useful in the treatment of central nervous system diseases and disorders which are responsive to modulation of the GABAA receptor complex.

A compound of Formula I includes a stereoisomer thereof and / or a salt thereof; wherein R1 is a substituted alkane group, a heterocylic group, or a pyridine group; X is hydrogen, a halogen, an amino acid residue, a substituted amino acid residue, an alkyl group, or an ester. Such compounds may be used in pharmaceutical compositions and for the treatment of central nervous system (CNS) disorders:

A brain function improving agent prevents the onset of, treats, and / or ameliorates cognitive function impairment and depressive symptoms in central nervous system diseases. The agent contains as active ingredient, at least one among 5-(3,5-dihydroxyphenyl)-γ-valerolactone represented by formula (I), a salt of said compound, and a conjugate of said compound.

The invention discloses a bionic bacterial outer membrane nano-particle for drug delivery. The bionic bacterial outer membrane nano-particle is characterized by comprising low-toxicity outer membrane vesicles extracted from escherichia coli with msbB genes knocked out, and low-toxicity outer membrane vesicles extracted from escherichia coli with msbB genes knocked out; the medicine carrying liposome is prepared from phosphatidylcholine, cholesterol and DSPE-PEG2000 (Distearoyl Phosphatidylcholine-Polyethylene Glycol 2000) according to a preset mass ratio; the low-toxicity outer membrane vesicles and the drug-loaded liposome are subjected to ultrasonic assistance and 100nm filter membrane extrusion to obtain bionic bacterial outer membrane nanoparticles, the average particle size of the bionic bacterial outer membrane nanoparticles is about 100nm, and the encapsulation efficiency exceeds 85%. The BM-NPs system disclosed by the invention can load small molecule compounds, proteins, nucleic acids and gene therapy vectors, and is suitable for various central nervous system diseases such as spinal cord injury, cerebral apoplexy, traumatic brain injury, ischemia-reperfusion injury and the like.

The present application provides methods of treating a CNS disorder (such as glioblastoma and epilepsy) in an individual, comprising systemically (e.g., intravenously or subcutaneously) administering to the individual an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, such as sirolimus or a derivative thereof) and an albumin, optionally further comprising administering a second agent (such as an anti-VEGF antibody, a proteasome inhibitor, or an alkylating agent).

The present invention relates to an adeno-associated virus (AAV) capsid protein variant having an amino acid mutation at the 328th to 331st amino acid residues of the AAV capsid protein relative to the 328th to 331st amino acid residues of the parent AAV capsid protein, for example, an amino acid sequence as shown in SEQ ID NO: 4 to replace the 328th to 331st amino acid residues of the parent AAV capsid protein wherein the amino acid position is numbered according to SEQ ID NO: 5. The invention also relates to an isolated nucleic acid encoding the AAV capsid protein variant, a nucleic acid vector comprising the same, and a host cell. The present invention also relates to a recombinant adeno-associated virus (rAAV) vector comprising the capsid protein variant, a pharmaceutical composition comprising the rAAV vector, and uses thereof in treatment or prevention of central nervous system diseases.

The invention relates to the technical field of exosome preparations, and particularly discloses an exosome nasal delivery preparation as well as a preparation method and application thereof. The preparation comprises the following components: 1 * 10 < 9 >-5 * 10 < 11 > particle number / ml of exosome, 1%-4% w / v of a saccharide protective agent, 0.5%-4.5% w / v of an alcohol protective agent, 0.05%-1% w / v of an absorption enhancer and a solvent. The exosome nasal delivery preparation can break through the blood brain barrier and quickly take effect, and the intracerebral delivery efficiency of the exosome nasal delivery preparation can be improved by 2-5 times compared with intravenous injection. The nasal administration preparation can be used for treating central nervous system diseases such as cerebral apoplexy and the like, and can remarkably improve the neurological function, reduce the cerebral infarction area and promote functional recovery.

The present invention relates to the use of recombinant porcine adeno-associated virus (AAV) vectors comprising peptide-modified porcine AAV serotype 1 (AAVpo1) capsids in the gene therapy of muscle and / or central nervous system (CNS) disorders, particularly neuromuscular diseases such as genetic neuromuscular diseases.

The present disclosure relates to methods of treating at least one symptom of a mental disorder or disease of the central nervous system in a subject by modulating the amount of GABA produced in the subject's gut. The present disclosure also relates to methods of culturing the bacterial strain new bacterial strains. Also disclosed are methods of identifying bacterial strains capable of producing GABA, and engineering strains to produce GABA.

Provided are a CAR-T cell having good blood-brain barrier permeability, a product, and a use. On the basis of the research on CAR-T cell therapy for central nervous system diseases, provided are a CAR-T cell having good blood-brain barrier permeability and a corresponding drug, for use in treating or relieving central nervous system diseases. Such a CAR-T cell uses a B cell maturation antigen as a target, and highly expresses a CXCR3 chemokine receptor and CCL1, CCL3 and CCL4 chemokines. Also provided is a product for testing and determining the blood-brain barrier permeability of the CAR-T cell, e.g., a probe, a reagent, and a kit, thereby accurately testing and determining the blood-brain barrier permeability of a certain CAR-T cell.

An orally administered composition positively mitigates the progression of central nervous system diseases such as Alzheimer's, Parkinson's and Multiple Sclerosis. The composition consists of a lipid based blood brain barrier transport medium (Base Transport Sub-Formula) to which other elements (Functional Targeting Compound) may be integrated to mediate specific chemo-neurological dysfunction. It may be administered through the mouth as droplets a spray medium or a chewable tablet.

The scheme provides a kind of engineered exosome double drug delivery system loaded with ergosterol and its preparation method and application, belongs to the field of nanomaterials and nanobiomedicine, based on the innovative ROS-responsive nanomaterial CHPG design, load the active ingredient ergosterol to play the role of treatment and repair, which realizes the blood-brain barrier penetration and precise drug release in lesion area through targeted functional modification;It is wrapped in the nasal mucosa-derived stem cell exosome to form a drug delivery system Exo@Erg-CHPG-M, which combines the natural biological characteristics of exosome and the precise targeting advantage of nanomicelle, significantly improves the drug delivery efficiency, in vitro and animal model verification show that, the system can improve the neurological impairment and brain tissue injury after ischemic stroke by synergistically regulating inflammation and neural repair pathways, the scheme provides a new technical scheme for the precise treatment of central nervous system diseases such as cerebral stroke.

The present invention relates to pharmaceutical compounds of Formula (I):as further described herein, and pharmaceutical compositions containing such compounds, as well as methods of using these compounds to modulate the activity of aryl hydrocarbon receptor (AhR) and to treat conditions comprising inflammation inside the intestinal tract and certain disorders of the central nervous system affected by the gut-brain axis, including IBD, ulcerative colitis, Crohn's disease, Huntington's disease, and multiple sclerosis.

Provided herein are CB1 ligand-containing compounds, methods of delivering said compounds, and methods of treating diseases, disorders, and symptoms (e.g., central nervous system diseases, disorders, and symptoms) in a subject using said compounds.

Provides *Parabacterium* strains, cultures, inoculants, and their applications. Specifically, provides a *Parabacterium* strain, which may be a strain with accession number GDMCC No: 62664 or 62665, or a strain with at least 96.74% identity to the strain's 16S rRNA and / or at least 87% average nucleotide identity to the strain's genome; the strain or products based on the strain have good preventive or therapeutic effects on tumors or cancers, metabolic diseases, inflammatory or autoimmune diseases, infectious diseases, and central nervous system diseases.

This invention relates to the packaging and screening of viral vectors, particularly to the packaging and screening of AAV mutants, specifically an adeno-associated virus mutant that efficiently infects HT-22 cells. By constructing a peptide mutant library of AAV9, a new AAV9 mutant with seven inserted amino acids was obtained through screening and verification. This mutant can effectively infect HT-22 cells at an MOI of 1E+5, achieving a higher infection rate than the natural AAV9 serotype at MOI=1E+5. The AAV9-HT01 mutant obtained after screening showed the best effect, with a significantly higher infection positivity rate compared to the control AAV9 serotype under the same MOI conditions. The fold increase was 4.4-fold as measured by luciferase (RLU) value detection. This effectively reduces the amount of AAV cells used for infection, saving experimental costs, and simultaneously makes it feasible to study the mechanisms of gene therapy for central nervous system diseases in HT-22 cells.

The invention provides an ergosterol-loaded engineered exosome double-drug-loading system as well as a preparation method and application thereof, belongs to the field of nano materials and nano biological medicines, and is based on innovative ROS response type nano material CHPG design, a therapeutic active component ergosterol is loaded to play a role in treatment and repair, and the curative effect of the ergosterol is improved. Blood-brain barrier penetration and accurate drug release in a focus area are realized through targeted function modification; the Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG- the nerve function defect and brain tissue damage after ischemic stroke are improved, and a new technical scheme is provided for precise treatment of central nervous system diseases such as cerebral stroke.

The application discloses CpG-containing oligodeoxynucleotide (ODN) with the function of regulating the body's immune capacity and application thereof. The oligodeoxynucleotide in the application is different from the design concept of traditional A-type CpG ODN in sequence and structure, embodies the complex drug-making rule and overcomes the problem of traditional A-type CPG in drug-making. The oligodeoxynucleotide has excellent activity of regulating the body's immune function in vitro and in vivo, can stimulate the production of I, II and III type interferons, regulates the Th1 type immune response, and inhibits the Th2 type and Th17 type inflammatory response. Therefore, the oligodeoxynucleotide can prevent and treat allergic diseases caused by Th2 type immune response, including allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophil and Th17 related diseases, can prevent and treat the infection and spread of respiratory or non-respiratory pathogenic microorganisms including viruses, bacteria, fungi and parasites, can improve the immune level of the elderly and immunodeficient population, can convert "cold tumor" into "hot tumor", improve the effect of cancer immunotherapy, can prevent and treat central nervous system diseases related to immune dysfunction such as Alzheimer's disease, and can be applied to other diseases related to immune dysfunction.

The application discloses application of a TAT-MK-ELE polypeptide in preparation of a central nervous system hypoxic disease prevention and treatment drug. In order to simulate the effect of MK-4, the TAT-MK-ELE polypeptide is designed and synthesized, and research proves that the TAT-MK-ELE polypeptide has a protective effect on hypoxic oligodendrocytes, can significantly improve the activity of the hypoxic oligodendrocytes, and can significantly inhibit the expression of proinflammatory factors in the hypoxic oligodendrocytes, thereby providing a reference for clinically preventing and treating central nervous system diseases caused by hypoxia by taking oligodendrocytes as a target.